GYRE
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Gyre Therapeutics completed the acquisition of Cullgen to form an integrated biopharma company across the U.S. and ChinaMay 4, 2026
- Gyre Therapeutics aligns with China’s CDE on conditional approval pathway and priority review for hydronidone after pre-NDA meetingJan 5, 2026
- Gyre Therapeutics announces completion of patient enrollment in Phase 3 clinical trial of pirfenidone capsules for treatment of pneumoconiosisOct 15, 2025
- Gyre Therapeutics begins dosing in Phase 1 study of F230 for pulmonary hypertension in ChinaJun 10, 2025